Eterna Therapeutics
ERNA
8 hedge funds and large institutions have $4.82M invested in Eterna Therapeutics in 2018 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
1.3% more ownership
Funds ownership: 29.95% → 31.25% (+1.3%)
0% more funds holding
Funds holding: 8 → 8 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$145K |
Top Sellers
ERNA Hedge Fund Activity: Q2 2018 in Review
8 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2018, worth a combined $4.82M — down 8.5% from $5.27M a quarter earlier.
Fund positioning in ERNA was balanced in Q2 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was AWM Investment Company, adding an estimated $145K.
- 8 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $4.82M of Eterna Therapeutics stock for Q2 2018, down 8.5% quarter-over-quarter.
- 0 funds opened new Eterna Therapeutics positions in Q2 2018 and 0 closed out.
- The largest Eterna Therapeutics buyer in Q2 2018 was AWM Investment Company, an estimated $145K added.
Based on aggregated 13F filings for Q2 2018.